Abbott Laboratories Key Emerging Markets revenue
Key Emerging Markets revenue at Abbott Laboratories came to $1.2B for the quarter to 30 Sep 2026, up 8.9% from a year earlier.
As Abbott Laboratories reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 4 Nov 2026.
By quarter
| Period ending | Key Emerging Markets revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $1.2B | up 8.9% | 4 Nov 2026 |
| 30 Jun 2026 | $1.2B | up 9.9% | 28 Jul 2026 |
| 31 Mar 2026 | $1.1B | up 12.8% | 29 Apr 2026 |
| 30 Sep 2025 | $1.1B | — | 29 Oct 2025 |
| 30 Jun 2025 | $1.1B | — | 30 Jul 2025 |
| 31 Mar 2025 | $965.0M | — | 30 Apr 2025 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Abbott Laboratories: Diabetes Care revenue · Core Laboratory revenue · Adult Nutritionals revenue · Pediatric Nutritionals revenue · Cancer Diagnostics revenue · Rapid and Molecular revenue · Electrophysiology revenue · Vascular revenue · Rhythm Management revenue · Rapid Diagnostics revenue · Structural Heart revenue · Heart Failure revenue · Neuromodulation revenue · Point of Care revenue · Molecular revenue · COVID-19 Testing revenue · Medical Devices revenue · Diagnostic Products revenue · Nutritional Products revenue · Established Pharmaceuticals revenue · financial statements
Every KPI and segment of ABT, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
